Iambic Therapeutics
AI-discovered small-molecule drugs.
About Iambic Therapeutics
Generative-AI drug discovery — multiple oncology candidates in clinical trials. Among the most advanced AI-pharma plays.
Pitch deck breakdown
How Iambic Therapeutics would pitch themselves.
Target customer
Customers in the Iambic Therapeutics space — typically operators or teams running into the problem this product solves.
Problem they solve
Generative-AI drug discovery — multiple oncology candidates in clinical trials. Among the most advanced AI-pharma plays. The category has historically been served by tools that miss the modern workflow this product is built around.
Key differentiator
Iambic Therapeutics differentiates on ai-discovered small-molecule drugs. Backed by Nextech + Catalio Capital Management, $220M+ raised — the company has resources + validation to compound this thesis. Founded by Tom Miller + team.
Go-to-market strategy
Growth-stage GTM — multi-channel revenue motion (direct enterprise sales, channel partnerships, marketplace listings). Vertical specialisation + verticalised AE teams targeting enterprise + mid-market.
Company facts
- Category
- Other
- Funding stage
- Series C
- Total raised
- $220M+
- Founded
- 2020
- Team size
- 51-200
- HQ
- San Diego
- Country
- United States
- Website
- iambic.ai
Founders of Iambic Therapeutics
- Tom Miller
- Fred Manby
Investors backing Iambic Therapeutics
- Nextech
- Catalio Capital Management
Frequently asked questions
What does Iambic Therapeutics do?
Generative-AI drug discovery — multiple oncology candidates in clinical trials. Among the most advanced AI-pharma plays.
Where is Iambic Therapeutics based?
Iambic Therapeutics is based in San Diego, United States.
When was Iambic Therapeutics founded?
Iambic Therapeutics was founded in 2020.
How much has Iambic Therapeutics raised?
Iambic Therapeutics has raised $220M+ in their Series C round.
Who founded Iambic Therapeutics?
Iambic Therapeutics was founded by Tom Miller, Fred Manby.
Who has invested in Iambic Therapeutics?
Iambic Therapeutics is backed by Nextech, Catalio Capital Management.